Gefapixant

Gefapixant
Clinical data
ATC code	R05DB29 (WHO) ;
Identifiers
	IUPAC name 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide;
CAS Number	1015787-98-0;
PubChem CID	24764487;
DrugBank	DB15097;
ChemSpider	58828660;
UNII	6K6L7E3F1L;
KEGG	D11349;
ChEMBL	ChEMBL3716057;
ECHA InfoCard	100.258.106
Chemical and physical data
Formula	C14H19N5O4S
Molar mass	353.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC;
	InChI InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19); Key:HLWURFKMDLAKOD-UHFFFAOYSA-N;

Gefapixant (MK-7264) is a drug which acts as an antagonist of the P2RX3 receptor, and may be useful in the treatment of chronic cough.[1][2][3] It was named in honour of Geoff Burnstock.[4]

References

Muccino D, Green S (June 2019). "Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough". Pulmonary Pharmacology & Therapeutics. 56: 75–78. doi:10.1016/j.pupt.2019.03.006. PMID 30880151.
Richards D, Gever JR, Ford AP, Fountain SJ (July 2019). "Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation". British Journal of Pharmacology. 176 (13): 2279–2291. doi:10.1111/bph.14677. PMC 6555852. PMID 30927255.
Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, Lambertucci C (December 2019). "Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications". Expert Opinion on Therapeutic Patents. 29 (12): 943–963. doi:10.1080/13543776.2019.1693542. hdl:11581/435751. PMID 31726893. S2CID 208037373.
Ford, Anthony P.; Dillon, Michael P.; Kitt, Michael M.; Gever, Joel R. (November 2021). "The discovery and development of gefapixant". Autonomic Neuroscience. 235: 102859. doi:10.1016/j.autneu.2021.102859.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid30880151-1] Muccino D, Green S (June 2019). "Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough". Pulmonary Pharmacology & Therapeutics. 56: 75–78. doi:10.1016/j.pupt.2019.03.006. PMID 30880151.

[pmid30927255-2] Richards D, Gever JR, Ford AP, Fountain SJ (July 2019). "Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation". British Journal of Pharmacology. 176 (13): 2279–2291. doi:10.1111/bph.14677. PMC 6555852. PMID 30927255.

[pmid31726893-3] Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, Lambertucci C (December 2019). "Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications". Expert Opinion on Therapeutic Patents. 29 (12): 943–963. doi:10.1080/13543776.2019.1693542. hdl:11581/435751. PMID 31726893. S2CID 208037373.

[4] Ford, Anthony P.; Dillon, Michael P.; Kitt, Michael M.; Gever, Joel R. (November 2021). "The discovery and development of gefapixant". Autonomic Neuroscience. 235: 102859. doi:10.1016/j.autneu.2021.102859.